<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379209</url>
  </required_header>
  <id_info>
    <org_study_id>RGI-2001-02</org_study_id>
    <nct_id>NCT01379209</nct_id>
  </id_info>
  <brief_title>Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)</brief_title>
  <official_title>A Phase 1/2a, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regimmune Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regimmune Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to&#xD;
      evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients&#xD;
      undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment.&#xD;
&#xD;
      The study will be separated into two parts; a dose escalation phase to assess safety,&#xD;
      followed by a large expansion phase to further evaluate the pharmacologic effects of either a&#xD;
      Maximum Tolerated Dose, Maximum Feasible Dose or optimal pharmacologically active dose of&#xD;
      RGI-2001. The initial dose escalation safety portion of the study (Part 1) will include&#xD;
      higher risk patients and limit the unrelated donor transplants. After safety is established&#xD;
      in part 1 of the study, the second portion of the study will expand the enrollment criteria&#xD;
      and allow transplantation by either related or unrelated donors.&#xD;
&#xD;
      This study will endeavor to identify the dose range at which RGI-2001 has an acceptable&#xD;
      safety profile, at which biologic activity is observed, and to guide possible dose levels to&#xD;
      utilize in later phase studies based on biological activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to&#xD;
      evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients&#xD;
      undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment.&#xD;
&#xD;
      In Part 1 (Phase 1: Dose Escalation Phase), patients will receive a single intravenous&#xD;
      administration of RGI-2001 approximately 30 minutes after completion of the transplant&#xD;
      (either allogeneic PBSCs or allogenic bone marrow transplantation (unmodified)) with the&#xD;
      dosage based upon the assigned treatment cohort. Eligible patients will be enrolled in five&#xD;
      to seven centers in the United States. Patients who are undergoing AHSCT will be enrolled in&#xD;
      a sequential group dose-escalating fashion to determine the safety, tolerability,&#xD;
      pharmacokinetic profile, and the MTD or MFD of RGI-2001. It is anticipated that up to six&#xD;
      dose levels will be evaluated in Part 1, with an option for an additional cohort (Cohort 7)&#xD;
      if the MTD is not reached and pharmacodynamic markers suggest higher doses are warranted.&#xD;
&#xD;
      In Part 2 (Expansion Phase), one or more doses below the MTD or MFD will be selected based on&#xD;
      a potential correlation between GvHD and biological activity to further assess safety and&#xD;
      biologic activity. Approximately 30 patients who are undergoing either allogeneic PBSCs or&#xD;
      allogenic bone marrow transplantation (unmodified) will be enrolled in Part 2 of the study.&#xD;
&#xD;
      Patients will be monitored for safety for 29 days after the transplant procedure.&#xD;
&#xD;
      All patients will be followed for 100 days following transplant procedure for the incidence&#xD;
      of acute GvHD, according to the Modified Keystone Criteria for grading acute GvHD (Przepiorka&#xD;
      D, et al)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) or maximum feasible dose (MFD) of RGI-2001</measure>
    <time_frame>By day 29</time_frame>
    <description>The primary outcome measures are:&#xD;
The incidence and severity of adverse events&#xD;
The maximum tolerated dose (MTD) or maximum feasible dose (MFD) of RGI-2001, administered as a single intravenous infusion approximately 30 minutes after AHSCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects</measure>
    <time_frame>Within 100 days from AHSCT</time_frame>
    <description>Evaluate biomarkers to assess the potential pharmacodynamic effects of RGI-2001 through biomarkers and cytokine assessments. Exploratory biomarkers for efficacy in reducing GvHD include IL-2R, TNFR1, HGF. Cytokines will be evaluated for both safety and for evidence of mechanism of action and include IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, MIG, TNF-α and IFN-γ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RGI-2001</measure>
    <time_frame>Within first 8 days</time_frame>
    <description>Obtain pharmacokinetic parameters such as Cmax, Cmin, Tmax, AUC and half-life of the study drug in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in reducing the intensity of GvHD</measure>
    <time_frame>Within the first 100 days after AHSCT</time_frame>
    <description>The time to onset, peak intensity and course of GvHD after the AHSCT procedure will be monitored according to the Modified Keystone Criteria for Acute Graft-Versus-Host Disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal Dose of RGI-2001</measure>
    <time_frame>Within first 100 days after AHSCT</time_frame>
    <description>Determine optimal doses of RGI-2001 for further evaluation based on pharmacodynamic response and effectiveness in reducing the intensity of GvHD</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols&#xD;
Dose escalation cohort 1 in part 1 of this study will include 2-6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols&#xD;
Cohort 2 in part 1 of this study will include 2-6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols&#xD;
Cohort 3 in part 1 of this study will include 2-6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols&#xD;
Cohort 4 in part 1 of this study will include 2-6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols&#xD;
Cohort 5 in part 1 of this study will include 2-6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols&#xD;
Cohort 6 in part 1 of this study will include 2-6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols&#xD;
Cohort 7 in part 1 of this study will include 2-6 patients (optional)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols&#xD;
In part 2 of this study the best dose or doses determined from part 1 will be administered in up to 30 persons.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RGI-2001</intervention_name>
    <description>A single administration of RGI-2001 on Day 0 post AHSCT.</description>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <other_name>KRN-7000</other_name>
    <other_name>RGI-7000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcineurin Inhibitors</intervention_name>
    <description>GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.</description>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>According to institutional guidelines.</description>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conditioning Regimen</intervention_name>
    <description>Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.</description>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>According to institutional guidelines</description>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <other_name>Administered for GVHD prophylaxis as per institutional guidelines</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mofetil Mycophenolate</intervention_name>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <other_name>Administered for GVHD prophylaxis as per institution guidelines</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>Administered for GVHD prophylaxis as per institutional guidelines</description>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has a hematological malignancy or aplastic anemia (AA) and is undergoing a&#xD;
             first allogeneic transplant procedure.&#xD;
&#xD;
          2. Meet one of the following underlying disease criteria:&#xD;
&#xD;
             a. Acute myelogenous leukemia (AML) i. First or subsequent morphologic remission b.&#xD;
             Acute lymphoblastic leukemia (ALL) i. First or subsequent morphologic remission c.&#xD;
             Chronic myelogenous leukemia (CML) i. Chronic phase; or ii. Accelerated phase d.&#xD;
             Multiple Myeloma (MM) i. Not more than 20% plasma cells in the bone marrow e.&#xD;
             Myelodysplastic syndrome (MDS), including chronic myelomonocytic leukemia (CMML), who&#xD;
             have received at least one previous induction regimen and have &lt;10% blasts f.&#xD;
             Myeloproliferative disorder (MPD), including; i. myeloid metaplasia, and ii.&#xD;
             myelofibrosis g. Non-Hodgkin's Lymphoma (NHL) i. High-risk NHL in first remission; or&#xD;
             ii. Relapsed or refractory NHL h. Hodgkin's lymphoma (HL) beyond first remission i.&#xD;
             Aplastic anemia (AA)&#xD;
&#xD;
          3. Male or female, age ≥18 years of age&#xD;
&#xD;
          4. Reasonable expectation of survival for at least 3 months, if the transplant procedure&#xD;
             is successful&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) status of 0-2 or Karnofsky Performance&#xD;
             Status (KPS) of &gt; 60&#xD;
&#xD;
          6. Transplant Donor&#xD;
&#xD;
               1. Part 1 (Phase 1: Dose Escalation Phase):&#xD;
&#xD;
                  Unrelated transplant donor with no more than 1 HLA allele or antigen mismatch,&#xD;
                  defined as loci A, B, C and DR (note: DQ is excluded)&#xD;
&#xD;
               2. Part 2 (Phase 2a: Expansion Phase):Related or unrelated transplant donor, with no&#xD;
                  more than 1 HLA allele or antigen mismatch, defined as loci A, B, C and DR (note:&#xD;
                  DQ is excluded).&#xD;
&#xD;
          7. Source of the allograft&#xD;
&#xD;
               1. Part 1 (Phase 1: Dose Escalation Phase):Unmodified (non-manipulated) bone marrow,&#xD;
                  or mobilized peripheral blood stem cell (PBSC) transplant, using G-CSF as the&#xD;
                  mobilizing agent.&#xD;
&#xD;
               2. Part 2: (Phase 2a: Expansion Phase) Unmodified (non-manipulated) bone marrow, or&#xD;
                  mobilized peripheral blood stem cell (PBSC) transplant, using G-CSF as the&#xD;
                  mobilizing agent.&#xD;
&#xD;
          8. Anti-graft-versus-host disease (GvHD) prophylaxis:&#xD;
&#xD;
             A calcineurin inhibitor [either tacrolimus (FK506) or cyclosporin A)], in combination&#xD;
             with either methotrexate (MTX), mycophenolate mofetil (MMF) or sirolimus (RAPA) all at&#xD;
             doses as per the institutional protocols&#xD;
&#xD;
          9. Adequate hepatic function, with bilirubin not exceeding the upper limit of normal&#xD;
             (except when attributed to Gilbert's Disease), and AST and ALT of less than 1.5 times&#xD;
             the upper limit of normal&#xD;
&#xD;
         10. No clinically significant cardiac conduction disorder on screening ECG&#xD;
&#xD;
         11. Serum creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
         12. Female patients of childbearing potential must have a negative serum pregnancy test&#xD;
             prior to enrollment and must agree to use dual method of contraception for 30 days&#xD;
             after study drug administration. Approved methods of contraception include, an IUD&#xD;
             with spermicide, a female condom with spermicide, a diaphragm with spermicide, a&#xD;
             cervical cap with spermicide, use of a condom with spermicide by sexual partner or a&#xD;
             sterile sexual partner.&#xD;
&#xD;
         13. If male, subjects must be sterile or willing to use an approved method of&#xD;
             contraception from the time of Informed Consent to 30 days after study drug treatment.&#xD;
             Males must be willing to refrain from sperm donation within 30 days after study drug&#xD;
             treatment.&#xD;
&#xD;
         14. No clinically significant acute or chronic medical condition that in the opinion of&#xD;
             the investigator will interfere with study participation&#xD;
&#xD;
         15. No clinically significant laboratory abnormalities as determined by the Principal&#xD;
             Investigator, in consultation with the Sponsor's Medical Monitor&#xD;
&#xD;
         16. No active infection&#xD;
&#xD;
         17. Have signed written informed consent before undergoing any study related procedures&#xD;
             and is willing to comply with all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who are pregnant or lactating&#xD;
&#xD;
          2. Subjects about to undergo a non-ablative or non-myeloablative transplant&#xD;
&#xD;
          3. AML or ALL patient who are in relapse (&gt;5% blasts) or who are defined as primary&#xD;
             refractory&#xD;
&#xD;
          4. Blast crisis CML&#xD;
&#xD;
          5. Radiation, chemotherapy, immunotherapy in the previous 3 weeks, unrelated to the&#xD;
             transplant procedure&#xD;
&#xD;
          6. Subjects who, in the judgment of the Investigator have not recovered from the effects&#xD;
             of previous therapy&#xD;
&#xD;
          7. Subject who is about to undergo cord blood transplantation&#xD;
&#xD;
          8. Procedures that are intended to deplete regulatory T-cells from donor transplant&#xD;
             materials&#xD;
&#xD;
          9. Known or suspected HIV infection&#xD;
&#xD;
         10. Active hepatitis A, B, or C infection in recipient or donor&#xD;
&#xD;
         11. Uncontrolled active infection requiring IV antibiotics in recipient or donor&#xD;
&#xD;
         12. Major surgery within 1 month before Day 0&#xD;
&#xD;
         13. Participation in an investigational study within 1 month prior to Day 0&#xD;
&#xD;
         14. Prior treatment with anti-CD3 antibodies&#xD;
&#xD;
         15. Treatment with anti-CD20 antibodies or anti-thymocyte globulin (ATG) within 3 months&#xD;
             of the AHSCT procedure (i.e. infusion of transplant material and RGI-2001).&#xD;
&#xD;
         16. Vaccination within the preceding 2 weeks prior to the planned dose of RGI-2001&#xD;
&#xD;
         17. Planned vaccination within 2 months after study drug administration&#xD;
&#xD;
         18. Known history of cardiac dysfunction (e.g. &lt;50% ejection fraction), ischemia,&#xD;
             conduction abnormalities, or myocardial infarction in the previous six months&#xD;
&#xD;
         19. Cardiac pacemaker or automatic implantable cardioverter-defibrillator&#xD;
&#xD;
         20. Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc&#xD;
             interval &gt;450 ms&#xD;
&#xD;
         21. Congenital long QT syndrome or family history of long QT syndrome&#xD;
&#xD;
         22. History of additional risk factors for torsades de pointes (TdP) (e.g., heart failure,&#xD;
             hypokalemia)&#xD;
&#xD;
         23. Bundle branch block&#xD;
&#xD;
         24. Connective tissue/rheumatologic disorders&#xD;
&#xD;
         25. History of autoimmune disease&#xD;
&#xD;
         26. History of solid tumor, excluding non-melanoma skin or cervical carcinoma after&#xD;
             curative resection, within the preceding 5 years&#xD;
&#xD;
         27. Uncontrolled diabetes&#xD;
&#xD;
         28. Prior allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
         29. Any other prior organ transplant&#xD;
&#xD;
         30. Psychiatric or addictive disorders that preclude obtaining reliable informed consent&#xD;
&#xD;
         31. Any other condition that, in the opinion of the investigator, renders the subject&#xD;
             unsuitable for study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD Moores Cancer Research Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>93093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center - The James</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.regimmune.com</url>
    <description>Regimmune Company Website</description>
  </link>
  <link>
    <url>http://www.fhcrc.org</url>
    <description>Fred Hutchinson Cancer Research Center</description>
  </link>
  <link>
    <url>http://med.stanford.edu</url>
    <description>Stanford School of Medicine</description>
  </link>
  <link>
    <url>http://cancer.ucsd.edu/Pages/default.aspx</url>
    <description>UCSD Moores Cancer Center</description>
  </link>
  <link>
    <url>http://cancer.osu.edu/Pages/index.aspx</url>
    <description>OSU The James Comprehensive Cancer Center</description>
  </link>
  <link>
    <url>http://www.dfhcc.harvard.edu/membership/profile/member/1498/0/</url>
    <description>Dana Farber / Mass General Link to Yi-Bin Chen</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 17, 2011</study_first_submitted>
  <study_first_submitted_qc>June 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <disposition_first_submitted>June 27, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>September 30, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 9, 2019</disposition_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AHSCT</keyword>
  <keyword>Bone Marrow Transplant</keyword>
  <keyword>Leukemia</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>hematological malignancies</keyword>
  <keyword>Graft-versus-host-disease</keyword>
  <keyword>GvHD</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Stem Cell</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>KRN 7000</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

